Market Report, "Myriad Genetics, Inc. (MYGN) - Product Pipeline Analysis, 2014 Update", published

Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The company undertakes the discovery and commercialization of molecular diagnostic tests that assesses person's risk towards disease development, disease progression and recurrence and guide through the treatment decisions. Its product portfolio iincludes nine commercial molecular diagnostic tests, namely, six predictive medicine tests; one prognostic medicine test; and two personalized medicine tests in the areas of oncology and CNS related disorders. Its commercial molecular diagnostic tests comprise BRACAnalysis, COLARIS, MELARIS, PANEXIA, COLARIS AP, PREZEON, TheraGuide, TruCulture, DiscoveryMAP, Prolaris and RodentMap The company along with its subsidiaries operates in the US, Spain, France, Switzerland, the UK, Canada, the Netherlands and Italy. The company is headquartered in Salt Lake City, Utah, the US.

The company mainly focuses on three key initiatives, namely, to grow and expand its existing products and markets, to develop its business internationally and have established operations in Europe, and to introduce new transformative products across a diverse set of disease indications, complementing its current businesses in oncology, women's health and urology.

Full Report Details at
- http://www.fastmr.com/prod/823655_myriad_genetics_inc_mygn_product_pipeline.aspx?afid=301

This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

* The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
* The report analyzes all pipeline products in development for the company Myriad Genetics, Inc.
* The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
* The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
* The report provides detailed description of products in development, technical specification and functions
* The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

* Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
* Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Insight Genetics, Inc. - Product Pipeline Analysis, 2014 Update
- Myriad Genetics, Inc. (MYGN) - Medical Equipment - Deals and Alliances Profile
- Signal Genetics LLC - Product Pipeline Analysis, 2013 Update
- Cancer Genetics, Inc. (CGIX) - Product Pipeline Analysis, 2013 Update
- Atlas Genetics Ltd. - Product Pipeline Analysis, 2013 Update